Evidence map›Paper›PMID 41852710›Full record

ArticleOpen medicine (Warsaw, Poland)2026

Retrospective analysis of adverse drug reaction patterns from the national monitoring system in a tertiary care hospital in China (2019-2024).

Xiao-Lei Yuan, Xiao-Yu Fang, Feng Li, Feng-Jun Wang, Qian-Qian Ma, Jun-Tao Chen, Ya-Nan Wang

Abstract read
In one paragraph

Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiao-Lei YuanDepartment of Pharmacy, Jieshou People's Hospital, Fuyang, Anhui Province, China.ORCID https://orcid.org/0009-0009-9447-7558
Xiao-Yu FangDepartment of Pharmacy, Jieshou People's Hospital, Fuyang, Anhui Province, China.ORCID https://orcid.org/0009-0005-8696-252X
Feng LiDepartment of Pharmacy, Jieshou People's Hospital, Fuyang, Anhui Province, China.
Feng-Jun WangDepartment of Pharmacy, Jieshou People's Hospital, Fuyang, Anhui Province, China.ORCID https://orcid.org/0009-0003-9503-6283
Qian-Qian MaDepartment of Pharmacy, Jieshou People's Hospital, Fuyang, Anhui Province, China.ORCID https://orcid.org/0009-0003-0132-0137
Jun-Tao ChenDepartment of Pharmacy, Jieshou People's Hospital, Fuyang, Anhui Province, China.ORCID https://orcid.org/0009-0006-5753-3248
Ya-Nan WangDepartment of Pharmacy, Jieshou People's Hospital, Fuyang, Anhui Province, China.ORCID https://orcid.org/0009-0004-9756-6218

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: To characterize the patterns, risk factors, and reporting trends of adverse drug reactions (ADRs) in a tertiary care hospital in China to inform targeted medication safety interventions. Methods: A single-center, retrospective analysis was conducted on 5,564 ADR reports extracted from the National Adverse Drug Reaction Monitoring System (2019-2024). Reports were assessed for causality using the WHO-UMC criteria. Descriptive statistics and chi-squared tests were employed to analyze demographics, reporting trends, causative drugs, administration routes, and clinical outcomes. Results: The mean patient age was 62.4 years, with males slightly predominating (52.5 %). ADR reporting increased markedly over the study period, with pharmacists becoming the primary reporters (93.1 % in 2024). Intravenous infusion was the most common route (67.3 %). Antineoplastic agents were the predominant drug class implicated (34.2 %), followed by anti-infectives (10.8 %) and cardiovascular drugs (9.4 %). Statistically significant associations were found between ADR outcomes and both the type of ADR (new/serious vs. general, p<0.001) and the administration route (intravenous vs. oral, p<0.001). No significant association was observed between patient age and ADR outcomes (p=0.244). Conclusions: Antineoplastic drugs and intravenous administration are key ADR risk factors. Enhanced monitoring of high-risk medications and optimized infusion protocols are needed. Limitations include retrospective single-center design and reporting biases.

Indexed as

adverse drug reactions (ADRs)retrospective analysisrisk factors

Identifiers

PMID41852710
PMCPMC12995258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.